Kenvue (KVUE) Earnings Date & Reports

Key Takeaways

• Kenvue is expected to report third-quarter (Q3) 2026 results in early November 2026, before the market opens.
• Analysts on average forecast adjusted earnings per share (EPS) of roughly $0.28 to $0.29, broadly in line with the $0.28 reported in the same quarter a year ago.
• Consensus revenue estimates sit near $3.86 billion, up from $3.76 billion in Q3 2025.
• Investors are closely watching margins, which have been pressured by inflation, tariffs, and currency headwinds.
• The pending $40 billion acquisition of Kenvue by Kimberly-Clark, expected to close in Q4 2026, dominates the strategic backdrop for this report.
• Kenvue has beaten consensus EPS estimates in six of its last eight quarters.

Earnings Context and Why It Matters

Kenvue is the world's largest pure-play consumer health company by revenue, with iconic brands including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol. Its quarterly earnings offer a read on consumer health demand, pricing power, and margin resilience across categories such as self care, skin health, and beauty. The Q3 2026 report carries added weight because the company is being acquired by Kimberly-Clark in a deal expected to close in the fourth quarter of 2026. In the most recent quarter, Kenvue posted adjusted EPS of $0.31, narrowly missing consensus, while revenue of $3.96 billion also came in slightly below expectations. That mixed result makes the upcoming print a key test of whether cost pressures and demand trends are stabilizing.

Earnings Expectations

For Q3 2026, the analyst consensus calls for adjusted EPS in the range of approximately $0.28 to $0.29, roughly flat versus the $0.28 Kenvue reported in the year-ago period. Revenue is expected to come in near $3.86 billion, which would represent year-over-year growth of about 2.6% from $3.76 billion a year earlier.

Beyond the headline numbers, investors will focus on organic sales growth, which reflects underlying demand after stripping out currency swings and deal-related effects. Adjusted gross margin will also be in focus after it declined to 60.2% in Q2 2026 from 60.9% a year earlier, as inflation, tariffs, and currency-related costs outweighed supply-chain savings and higher prices. Management has flagged roughly $250 million in pretax restructuring charges for 2026 tied to simplifying operations and cutting costs.

Historically, Kenvue has been a reliable earnings performer, beating consensus EPS in six of the last eight quarters. However, the stock's reaction has been uneven, underscoring that investors weigh margins and guidance as heavily as the headline EPS beat or miss.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking consumer health names or looking to build watchlists around earnings season, the AI Screener can help surface relevant candidates before the market opens.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 2026 report is cautious. Kenvue shares fell about 2.5% on August 6, 2026, after the company reported weaker-than-expected Q2 results and highlighted ongoing margin pressure. The stock has lagged the broader S&P 500 over the past 52 weeks, and analyst sentiment skews conservative, with most covering analysts maintaining a "Hold" rating.

The pending acquisition by Kimberly-Clark adds a distinctive layer to investor sentiment. With the deal expected to close in Q4 2026, some investors may focus less on short-term earnings fluctuations and more on transaction execution. Key risk factors include any signs of slowing organic sales, further margin compression from tariffs and foreign exchange, and potential complications in completing the acquisition.

Forward Outlook and Key Factors to Monitor

Looking past the Q3 2026 report, the most important catalyst for Kenvue is the completion of its acquisition by Kimberly-Clark. The deal's timing, regulatory clearances, and integration planning will shape how investors interpret the company's standalone results. Until the transaction closes, the market will likely weigh Kenvue's fundamentals alongside deal-related milestones.

Investors should also watch cost and margin trends. Management has been working to offset inflation, tariffs, and currency headwinds through supply-chain savings and pricing, but these benefits have not fully protected profitability. Whether adjusted gross margin stabilizes or recovers will be a key signal on the company's operating momentum.

Demand trends across core categories such as self care and skin health remain important. Organic sales growth will indicate whether consumers are holding up amid cautious spending. Finally, any updates on the company's restructuring program and its progress on simplification initiatives will help investors gauge the path toward more efficient operations. As always, no single quarter should be read in isolation, and the broader consumer staples environment will continue to influence results.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations